GleamWall
中文EN

BBNX Beta Bionics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1674632 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY43.7%
TTM net income YoY-6.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin58.6%
Operating margin-72.7%
Net margin-65.3%
FCF margin-51.8%
EBITDA margin-70.6%

Returns

ROE-23.9%
ROA-21.5%
ROIC (approx.)-25.4%
Asset turnover0.33x

Leverage & solvency

Liabilities / assets9.5%
Debt / equity0.00x
Current ratio8.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$35.51M$32.01M$27.63M$32.12M$27.25M$23.24M$17.64M$20.44M
Cost of revenue$15.17M$13.11M$11.19M$13.18M$12.13M$10.73M$8.67M$8.75M
Gross profit$20.33M$18.90M$16.44M$18.94M$15.12M$12.50M$8.97M$11.69M
R&D expense$11.97M$10.24M$10.36M$10.13M$8.20M$8.87M$7.59M$9.21M
SG&A expense$9.84M$9.60M$9.62M$8.60M$7.92M$7.88M$6.62M$4.71M
Operating income-$26.61M-$25.58M-$24.27M-$16.12M-$17.04M-$19.87M-$18.64M-$13.04M
Net income-$24.35M-$23.40M-$21.89M-$13.47M-$14.21M-$16.87M-$28.66M-$18.11M
EBITDA-$25.72M-$24.87M-$23.69M-$15.59M-$16.66M-$19.52M-$18.34M-$12.80M
EPS (basic)-0.52-0.53-0.49—-0.33-0.39-0.93—
EPS (diluted)-0.52-0.53-0.49—-0.33-0.39-0.93—
Weighted avg. shares (diluted)46.54M44.55M44.44M—43.63M43.39M30.71M—
Balance sheet
Cash & equivalents$81.55M$44.32M$30.21M$31.58M$38.48M$35.08M$42.45M$30.53M
Short-term investments$158.65M$136.17M$169.31M$187.55M$190.20M$214.65M$189.02M$73.14M
Receivables$20.67M$18.05M$15.75M$17.12M$11.54M$11.39M$9.06M$12.00M
Inventory$22.97M$23.92M$23.73M$21.72M$20.37M$17.32M$15.73M$13.32M
Current assets$292.95M$231.03M$247.99M$267.90M$270.03M$286.07M$261.92M$132.92M
PP&E, net$11.76M$10.75M$10.16M$8.60M$7.38M$6.46M$5.51M$4.78M
Total assets$443.76M$292.39M$304.42M$328.74M$330.05M$329.97M$338.02M$149.65M
Current liabilities$32.84M$26.02M$23.19M$30.92M$25.39M$19.49M$16.49M$21.15M
Total liabilities$42.38M$36.02M$33.17M$41.13M$35.29M$28.34M$24.27M$73.63M
Shareholders' equity$401.38M$256.37M$271.25M$287.61M$294.76M$301.63M$313.75M-$245.36M
Shares outstanding54.36M44.98M44.56M44.36M43.99M43.47M43.35M6.67M
Cash flow statement
Operating cash flow-$12.29M-$14.62M-$23.83M-$8.63M-$8.73M-$13.59M-$19.98M-$14.28M
Capital expenditure$2.27M$1.04M$1.38M$1.90M$1.28M$1.78M$333,000$561,000
Free cash flow-$14.56M-$15.66M-$25.21M-$10.53M-$10.01M-$15.37M-$20.31M-$14.84M
Investing cash flow-$114.08M$26.93M$21.84M$658,000$9.49M$6.17M-$179.12M-$29.66M
Financing cash flow$163.60M$1.80M$623,000$1.06M$2.65M$42,000$211.12M$56.89M
Depreciation & amortization$892,000$709,000$585,000$538,000$385,000$347,000$303,000$232,000
Stock-based compensation$6.71M$7.02M$5.41M$4.30M$4.48M$4.80M$2.80M$1.55M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.